Vaxcyte's (PCVX) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Vaxcyte's stock has been reiterated with a "sell (D-)" rating by Weiss Ratings, reflecting ongoing concerns about the company's performance.
• Despite the negative rating from Weiss, there is a mixed outlook from other analysts, with the consensus rating being "Moderate Buy" and a target price of $106.25.
• The company's latest earnings report showed a loss of ($1.22) earnings per share, missing analysts' estimates and indicating challenges in achieving profitability.

Vaxcyte (NASDAQ:PCVX - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

Several other brokerages also recently weighed in on PCVX. Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, September 12th. They set a "neutral" rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $106.25.

Vaxcyte Price Performance

Shares of PCVX traded down $0.24 on Tuesday, reaching $43.57. The company's stock had a trading volume of 808,679 shares, compared to its average volume of 1,793,519. The stock has a market capitalization of $5.66 billion, a P/E ratio of -10.61 and a beta of 1.12. The stock's 50 day simple moving average is $33.68 and its two-hundred day simple moving average is $33.47. Vaxcyte has a 12-month low of $27.66 and a 12-month high of $118.62.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the firm earned ($1.10) EPS. Analysts expect that Vaxcyte will post -4.21 earnings per share for the current year.

Institutional Investors Weigh In On Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the stock. AlphaQuest LLC bought a new stake in shares of Vaxcyte during the first quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Vaxcyte during the first quarter valued at approximately $35,000. IFP Advisors Inc raised its position in shares of Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after buying an additional 1,306 shares during the last quarter. CWM LLC raised its position in shares of Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company's stock valued at $55,000 after buying an additional 1,115 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its position in shares of Vaxcyte by 81.6% during the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company's stock valued at $73,000 after buying an additional 867 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.